This article is more than 5 years old. Information may no longer be current.

VIDEO: Servier Pharmaceuticals executive highlights pipeline, ‘focus on the patients’

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

CHICAGO — David K. Lee, CEO of Servier Pharmaceuticals, provided HemOnc Today with an overview of the company during ASCO Annual Meeting.

Servier Pharmaceuticals — founded in late 2018 — has approximately 100 employees, and the goal is to double the size of the business within the next 5 years.

The company has two marketed products for acute lymphoblastic leukemia, and the pipeline includes chimeric antigen receptor T-cell therapies, monoclonal antibodies and bispecifics.

Servier Pharmaceuticals is part of Servier Group, which is involved in other therapeutic areas such as cardiology, diabetes, immunoinflammatory diseases and neuroscience.

Servier Group is owned by a nonprofit foundation.

“We’re a private company, but what that really means is we can truly focus on the patients,” Lee told HemOnc Today. “We don’t have investors and don’t pay dividends. All money we make gets reinvested in the company, patients, and research and development.” – by Mark Leiser